Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 99, No. 5, Year 2005
Notification
URL copied to clipboard!
Description
Preclinical studies have shown that curdlan sulphate (CRDS), a sulphated 1 → 3-β-D glucan, inhibits Plasmodium falciparum in vitro and down-modulates the immune response. A direct, non-specific effect on cytoadherence and rosetting may be predicted, as has been described with other sulphated polysaccharides, e.g. heparin. The anticoagulant effect of CRDS is 10-fold lower than heparin. Curdlan sulphate has, therefore, emerged as a candidate for adjunct medication in the treatment of severe/ cerebral malaria. Two clinical studies were conducted using CRDS as adjunct medication to conventional therapy (artesunate) in patients with severe and severe/cerebral malaria. Both studies were double-blind and placebo-controlled to evaluate the efficacy and safety of the combination. Curdlan sulphate appeared to reduce the severity of the disease process, e.g. fever clearance time was shortened. Due to the small number of patients, there was no difference in mortality. The two treatment arms in both studies showed similar results for all laboratory parameters. The only adverse event recorded during CRDS treatment was an increase in activated partial thromboplastin time. This can be monitored easily. It seems that the patients who may benefit most are severe/ cerebral cases with no organ damage on admission. © 2004 Royal Society of Tropical Medicine Hygiene. Published by Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Havlík, Ivan
South Africa, Johannesburg
University of the Witwatersrand
Looareesuwan, Sornchai
Thailand, Nakhon Pathom
Mahidol University
Vannaphan, Suparp
Thailand, Nakhon Pathom
Mahidol University
Wilairatana, Polrat
Thailand, Nakhon Pathom
Mahidol University
Krudsood, Srivicha
Thailand, Nakhon Pathom
Mahidol University
Thuma, Philip E.
Zambia
Macha Malaria Research Institute
Kozbor, Danuta
United States, Buffalo
Roswell Park Cancer Institute
Watanabe, Naohiro
Japan, Tokyo
The Jikei University School of Medicine
Kaneko, Yutaro
Japan, Chuo-ku
Ajinomoto co Inc
Japan, Higashiosaka
Kindai University
Statistics
Citations: 45
Authors: 9
Affiliations: 7
Identifiers
Doi:
10.1016/j.trstmh.2004.05.005
ISSN:
00359203
Research Areas
Disability
Health System And Policy
Infectious Diseases